Reuters logo
BRIEF-Novimmune says grants Tiziana an exclusive license to NI-1201
January 4, 2017 / 6:09 AM / a year ago

BRIEF-Novimmune says grants Tiziana an exclusive license to NI-1201

Jan 4 (Reuters) - Novimmune SA (IPO-NOVI.S):

    * Grants Tiziana an exclusive license to NI-1201, an anti-IL-6R monoclonal antibody for treatment of autoimmune and inflammatory diseases

    * Financial details were not disclosed Source text for Eikon: Further company coverage: (Gdynia Newsroom)

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below